ReleaseWire Connect

BioCorRx Inc. (OTCMKTS:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced it will host its grand opening ribbon cutting on Monday, June 5, at the Company's new corporate office in Anaheim, California. As previously announced this year, the Company is offering treatment services as part of the city's Drug Free Anaheim initiative. Anaheim Mayor Tom Tait will be in attendance at the event.

BioCorRx Inc. (OTCMKTS:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that the U.S. Food & Drug Administration (FDA) has granted a pre-IND meeting to the Company and it is scheduled to take place on Tuesday, September 19, 2017 in order to review the development plan to market BICX101, an injectable, sustained release naltrexone, for the treatment of opioid addiction and alcohol use disorders.

BioCorRx Inc. (OTCMKTS:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced it has filed an application for listing on the NASDAQ Capital Market®.

BioCorRx Inc. (OTCMKTS:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the first quarter ended March 31, 2017.

BioCorRx Inc. (OTCMKTS:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Brady Granier, BioCorRx CEO, President, and Director, appeared as a guest on Fox & Friends, this morning to discuss the naltrexone implant and BICX101, an injectable, sustained release naltrexone, for the treatment of opioid addiction and alcohol use disorders that BioCorRx is developing.

BioCorRx Inc. (OTCMKTS:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance use disorders, today announced it entered into an agreement with DynamiCare Health™, Inc. to develop a co-branded mobile application to support patients engaged in counseling for the treatment of alcoholism or opioid addiction and receiving long-term naltrexone treatment. DynamiCare Health is focused on building evidence-based tools that motivate people to live healthy lives.

BioCorRx Inc. (OTCMKTS:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Innovative Science Solutions, LLC (ISS), on behalf of BioCorRx, Inc., has formally requested a pre-IND meeting with the U.S. Food & Drug Administration (FDA) to review the development plan to market BICX101, an injectable, sustained release naltrexone, for the treatment of opioid addiction and alcohol use disorders.

BioCorRx Inc. (OTCMKTS:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that is has received updated data from preclinical studies for BICX101, a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism. The Company is pleased to announce that three different formulations were successful in reaching 28 days of sustained release of naltrexone. The Company also announced that it will have a booth in the exhibit hall at the American Society of Addiction Medicine (ASAM) conference in New Orleans this week. ASAM is the leading addiction medicine professional society in the U.S. representing over 4,300 physicians, clinicians and professionals with a focus on addiction and its treatment.

BioCorRx Inc. (OTCMKTS:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Brady Granier, BioCorRx CEO, President, and Director, appeared as a guest on Fox Business Network's Mornings with Maria, this morning to discuss the nation's opioid epidemic and the use of naltrexone for treatment.

BioCorRx Inc. (OTCMKTS:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, is pleased to announce that the Company's shares have been approved for quotation on the OTCQB®, and will continue to trade under the symbol BICX. Investors can find real-time quotes and market information for the company on www.otcmarkets.com.